Quantitative Investment Management LLC Takes Position in Zoetis Inc. $ZTS

Key Points

• Quantitative Investment Management LLC acquired 20,811 shares of Zoetis Inc. for approximately $3.43 million during the first quarter, as indicated in a recent SEC filing.
• Institutional investors now account for 92.80% of Zoetis's stock ownership, with significant new positions established by several large funds.
• Zoetis's recent quarterly earnings report showed an EPS of $1.76 and revenue of $2.46 billion, exceeding analyst expectations and reflecting a 4.2% year-over-year revenue growth.

Quantitative Investment Management LLC purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 20,811 shares of the company's stock, valued at approximately $3,426,000.

A number of other large investors have also made changes to their positions in ZTS. Nuveen LLC acquired a new position in Zoetis in the 1st quarter valued at approximately $616,375,000. Sarasin & Partners LLP acquired a new position in Zoetis in the 1st quarter valued at approximately $339,111,000. Mackenzie Financial Corp increased its stake in Zoetis by 4,158.3% in the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company's stock valued at $300,481,000 after buying an additional 1,782,110 shares during the period. GAMMA Investing LLC increased its stake in Zoetis by 14,731.3% in the 1st quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company's stock valued at $289,666,000 after buying an additional 1,747,423 shares during the period. Finally, Polen Capital Management LLC increased its stake in Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock valued at $1,448,401,000 after buying an additional 1,313,653 shares during the period. Institutional investors and hedge funds own 92.80% of the company's stock.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the transaction, the executive vice president directly owned 15,129 shares in the company, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.18% of the company's stock.

Zoetis Stock Performance

Shares of ZTS opened at $156.3180 on Friday. The company's fifty day moving average is $153.84 and its 200-day moving average is $158.52. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The firm has a market cap of $69.28 billion, a price-to-earnings ratio of 26.91, a price-to-earnings-growth ratio of 2.51 and a beta of 0.88. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same quarter in the prior year, the business posted $1.56 EPS. Zoetis's quarterly revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ZTS. UBS Group dropped their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Piper Sandler upped their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and dropped their price objective for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $202.43.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.